Short profile
Name: Restalyst

<table>
<thead>
<tr>
<th>Medical field</th>
<th>Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product type</td>
<td>Medical Devices, Diagnostics, and Therapeutics</td>
</tr>
<tr>
<td>Growth stage</td>
<td>Other</td>
</tr>
<tr>
<td>Team</td>
<td>&lt;10 people</td>
</tr>
</tbody>
</table>

Description of product:
Restalyst has successfully developed and launched three cancer tests for early detection of cancer for nose, stomach and liver cancer.
- GC-REAAD™ ITIH3 ELISA is intended for qualitative and semi-quantitative detection of human Inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3) proteins which aid in the diagnosis of gastric cancer.
- HCC-REAAD™ ERBB3 ELISA is intended for qualitative and semi-quantitative detection of human epidermal growth factor receptor 3 (ERBB3) proteins, aiding in the diagnosis of Hepatocellular Carcinoma.

Desired project goal: Please also elaborate on the primary outcome
The company is proposing the following project scopes:
- Clinical evaluation of GC-REAAD™ ITIH3 and HCC-REAAD™ ERBB3 ELISA using retrospective cohort of samples
- Performance evaluation under IVDR of GC-REAAD™ ITIH3 and HCC-REAAD™ ERBB3 ELISA

Desired project type: Please also elaborate on the following points, if applicable: population, intervention, study design etc.
Co-innovation, clinical and performance evaluation